

In the claims:

Claims 1-19. (Canceled)

1 20. (Previously presented) A method for treating follicular lymphoma in a subject comprising administering an amount of a composition comprising a soluble lymphotoxin-beta receptor (LT-beta-R) and a pharmaceutically acceptable carrier, such that treatment occurs.

Claims 21-23 (Canceled)

2 24. (Previously presented) The method of claim 20 wherein the subject is a mammal.

3 25. (Previously presented) The method of claim 24 wherein the subject is a human.

4 26. (Previously presented) The method according to claim 20 wherein the soluble lymphotoxin- β receptor comprises a ligand binding domain that can selectively bind to a surface LT ligand.

Claims 27-30. (Canceled)

5 31. (Currently amended) The method of claim 20, further comprising administering the administration to said subject of at least one chemotherapeutic agent.

6 32. (Currently amended) The method of claim 20, further comprising administering the administration to said subject of radiation treatments.

7 33. (Currently amended) The method of claim 20 further comprising administering the administration to said subject of radiation treatments or bone marrow transplantation.

Claims 34-35. (Canceled)

- 8
36. (Previously presented) The method of claim 20, wherein the treatment is tumor regression or arrest.
- 9
37. (Previously presented) The method of claim 20, wherein the soluble LT-beta-R comprises a soluble LT-beta-R fused to one or more heterologous protein domains.
- 10
38. (Currently amended) The method of claim 9, wherein the soluble LT-beta-R is fused to heterologous protein domain comprises a human immunoglobulin Fc domain.
- 11
39. (Previously presented) The method of claim 20, wherein the soluble LT-beta-R comprises an extracellular domain of LT-beta-R.
- 12
40. (Previously presented) The method of claim 20, wherein the soluble LT-beta-R is human LT-beta-R.
- 13
41. (Currently amended) The method of claim 40, wherein the soluble LT-beta-R immunoglobulin fusion further comprises a human immunoglobulin Fc domain.
- 14
42. (Previously presented) The method of claim 41, wherein the immunoglobulin is IgG1.
- 15
43. (Previously presented) A method for disrupting interaction of a B cell lymphoma with its environment in a subject, comprising administering to the subject a composition comprising a soluble LT-beta-R and a pharmaceutically acceptable carrier, such that disruption of the interaction of the B cell lymphoma with its environment occurs.
- 16
44. (Previously presented) The method of claim 43, wherein the interaction is between the B cell lymphoma and a follicular dendritic cell in the subject.
- 17
45. (Previously presented) The method of claim 43, wherein the disruption of the interaction results in inhibition of growth of the B cell lymphoma.

¹⁸
~~46.~~ (Previously presented) The method of claim ¹⁵~~43~~, wherein the soluble LT-beta-R comprises a soluble LT-beta-R fused to one or more heterologous protein domains.

¹⁹
~~47.~~ (Previously presented) The method of claim ¹⁸~~46~~, wherein the heterologous protein domain comprises a human immunoglobulin Fc domain.

²⁰
~~48.~~ (Previously presented) The method of claim ¹⁵~~43~~, wherein the soluble LT-beta-R comprises an extracellular domain of LT-beta-R.

²¹
~~49.~~ (Previously presented) The method of claim ¹⁵~~43~~, wherein the soluble LT-beta-R is human LT-beta-R.

²²
~~50.~~ (Previously presented) The method of claim ²¹~~49~~, wherein the LT-beta-R-immunoglobulin fusion comprises a human immunoglobulin Fc domain.

²³
~~51.~~ (Previously presented) The method of claim ²¹~~49~~, wherein the immunoglobulin is IgG1.

²⁴
~~52.~~ (New) A method for treating follicular lymphoma in a human subject, the method comprising administering to the subject a pharmaceutical composition comprising a polypeptide that comprises a soluble, ligand-binding domain of human lymphotoxin-beta receptor (LT-beta-R) fused to a human IgG1 Fc domain, such that treatment occurs.

²⁵
~~53.~~ (New) The method of claim 52, wherein the soluble, ligand-binding domain of human LT-beta-R comprises SEQ ID NO:1.